Heiner C. Bucher

Heiner C. Bucher

Auto-generated profile, based on publicly available information

Heiner C. Bucher

Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2005 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
MSMarco Studer
Marco Studer
MBMatthias Briel
Matthias Briel
BLBernd Leimenstoll
Bernd Leimenstoll
TGTracy R. Glass
Tracy R. Glass
HBHeiner C. Bucher
Heiner C. Bucher
Review from JAMA Internal Medicine — Effect of Different Antilipidemic Agents and Diets on Mortality — A Systematic Review

8 July 2000 in BMJ
Verified
Journal Article
Closed access
PDF file
HBHeiner C Bucher
Heiner C Bucher
PHPeter Hengstler
Peter Hengstler
CSChristian Schindler
Christian Schindler
GGGordon H Guyatt
Gordon H Guyatt
Objective: To determine whether percutaneous transluminal coronary angioplasty (angioplasty) is superior to medical treatment in non-acute coronary artery disease. Design: Meta-analysis of randomised controlled trials. Setting: Randomised controlled trials conducted worldwide and published between 1979 and 1998. Participants: 953 patients treated with angioplasty and 951 with medical treatment from six randomised controlled trials, three of which included patients with multivessel disease and pre-existing myocardial infarction. Main outcome measures: Angina, fatal and non-fatal myocardial infarction, death, repeated angioplasty, and coronary artery bypass grafting. Results: In patients treated with angioplasty compared with medical treatment the risk ratios were 0.70 (95% confidence interval 0.50 to 0.98; heterogeneity P<0.001) for angina; 1.42 (0.90 to 2.25) for fatal and non-fatal myocardial infarction, 1.32 (0.65 to 2.70) for death, 1.59 (1.09 to 2.32) for coronary artery bypass graft, and 1.29 (0.71 to 3.36; heterogeneity P<0.001) for repeated angioplasty. Differences in the methodological quality of the trials, in follow up, or in single versus multivessel disease did not explain the variability in study results in any analysis. Conclusions: Percutaneous transluminal coronary angioplasty may lead to a greater reduction in angina in patients with coronary heart disease than medical treatment but at the cost of more coronary artery bypass grafting. Trials have not included enough patients for informative estimates of the effect of angioplasty on myocardial infarction, death, or subsequent revascularisation, though trends so far do not favour angioplasty.

3 May 2006 in JAMA
Verified
Journal Article
Closed access
PDF file
MBMatthias Briel
Matthias Briel
GSGregory G. Schwartz
Gregory G. Schwartz
PTPeter L. Thompson
Peter L. Thompson
JLJames A. de Lemos
James A. de Lemos
MBMichael A. Blazing
Michael A. Blazing
ANAlain J. Nordmann
Alain J. Nordmann
Review from JAMA — Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes — A Meta-analysis of Randomized Controlled Trials — ContextThe short-term effects of early treatment with statins in patients after the onset of acute coronary syndromes (ACS) for the outcomes of death, myocardial infarction (MI), and stroke are unclear.ObjectiveTo evaluate relevant outcomes of patients from randomized controlled trials comparing early statin therapy with placebo or usual care at 1 and 4 months following ACS.Data Sources and Study SelectionSystematic search of electronic databases (MEDLINE, EMBASE, PASCAL, Cochrane Central Register) from their inception to August 2005, which was supplemented by contact with experts in the field. Two reviewers independently determined the eligibility of randomized controlled trials that compared treatment with statins with a control, were initiated within 14 days after onset of ACS, and had a minimal follow-up of 30 days. Trials with cerivastatin were only included in a sensitivity analysis.Data ExtractionInformation on baseline characteristics of included trials and patients, reported methodological quality, lipid levels, and clinical outcome was independently extracted by 2 investigators. Investigators from each included trial contributed additional data if necessary.Data SynthesisTwelve trials involving 13 024 patients with ACS were included in the meta-analysis. The risk ratios for the combined end point of death, MI, and stroke for patients treated with early statin therapy compared with control therapy were 0.93 (95% confidence interval [CI], 0.80-1.09; P = .39) at 1 month and 0.93 (95% CI, 0.81-1.07; P = .30) at 4 months following ACS. There were no statistically significant risk reductions from statins for total death, total MI, total stroke, cardiovascular death, fatal or nonfatal MI, or revascularization procedures (percutaneous coronary intervention or coronary artery bypass graft surgery). Sensitivity analyses with restriction to trials of high quality or with additional data from a large trial using cerivastatin indicated summary risk ratios even closer to 1.ConclusionBased on available evidence, initiation of statin therapy within 14 days following onset of ACS does not reduce death, MI, or stroke up to 4 months.

11 August 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
HBHeiner C. Bucher
Heiner C. Bucher
PTPeter Tschudi
Peter Tschudi
JYJames Young
James Young
PPPierre Périat
Pierre Périat
AWAntje Welge-Lüssen
Antje Welge-Lüssen
CSChristian Schindler
Christian Schindler
ACUTE RHINOSINUSITIS is one of the most common diagnoses and most frequent reasons for prescribing antibiotics in general practice.1,2 Although most cases of acute rhinosinusitis in primary care are caused by an uncomplicated viral infection, antibiotics are frequently prescribed.3 One reason for this overuse of antibiotics is the lack of a simple diagnostic test in primary care that allows physicians to accurately differentiate between acute viral and bacterial rhinosinusitis. Acute bacterial rhinosinusitis is a secondary infection that results from ostia obstruction and impaired mucous clearance caused by an upper respiratory tract infection. Additional diagnostic tests, such as sonography, cranial x-ray examinations, and computed tomography, are useful,4 but these tests have intermediate specificities for the diagnosis of acute bacterial rhinosinusitis, are not immediately available in general practice, and add additional costs to the diagnosis and treatment of a common condition. Thus, misclassification of acute viral rhinosinusitis is an important reason for overuse of antibiotics in general practice. This overuse contributes to the emergence and spread of antibiotic-resistant bacteria.5

6 March 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
AKAlexander Kutz
Alexander Kutz
MBMatthias Briel
Matthias Briel
MCMirjam Christ-Crain
Mirjam Christ-Crain
DSDaiana Stolz
Daiana Stolz
LBLila Bouadma
Lila Bouadma
PSPhilipp Schuetz
Philipp Schuetz
Introduction: Whether the inflammatory biomarker procalcitonin provides prognostic information across clinical settings and different acute respiratory tract infections (ARIs) is poorly understood. In the present study, we investigated the prognostic value of admission procalcitonin levels to predict adverse clinical outcome in a large ARI population. Methods: We analysed data from 14 trials and 4,211 ARI patients to study associations of admission procalcitonin levels and setting specific treatment failure and mortality alone at 30 days. We used multivariable hierarchical logistic regression and conducted sensitivity analyses stratified by clinical settings and ARI diagnoses to assess the results’ consistency. Results: Overall, 864 patients (20.5%) experienced treatment failure and 252 (6.0%) died. The ability of procalcitonin to differentiate patients with from those without treatment failure was highest in the emergency department setting (treatment failure area under the curve (AUC): 0.64 (95% confidence interval (CI): 0.61, 0.67), adjusted odds ratio (OR): 1.85 (95% CI: 1.61, 2.12), P <0.001; and mortality AUC: 0.67 (95% CI: 0.63, 0.71), adjusted OR: 1.82 (95% CI: 1.45, 2.29), P <0.001). In lower respiratory tract infections, procalcitonin was a good predictor of identifying patients at risk for mortality (AUC: 0.71 (95% CI: 0.68, 0.74), adjusted OR: 2.13 (95% CI: 1.82, 2.49), P <0.001). In primary care and intensive care unit patients, no significant association of initial procalcitonin levels and outcome was found. Conclusions: Admission procalcitonin levels are associated with setting specific treatment failure and provide the most prognostic information regarding ARI in the emergency department setting.

7 November 2005 in BMC Infectious Diseases
Verified
Journal Article
Open access
MBMatthias Briel
Matthias Briel
RBRemy Boscacci
Remy Boscacci
HFHansjakob Furrer
Hansjakob Furrer
HBHeiner C Bucher
Heiner C Bucher
Background: The objective of this study was to review the effects of adjunctive corticosteroids on overall mortality and the need for mechanical ventilation in HIV-infected patients with Pneumocystis jiroveci pneumonia (PCP) and substantial hypoxemia ( arterial oxygen partial pressure < 70 mmHg or alveolar-arterial gradient > 35 mmHg on room air). Methods: We conducted a systematic search of the literature for randomised trials published up to December 2004. Selected trials compared adjunctive corticosteroids with placebo or usual care in HIV-infected patients with PCP and reported mortality data. Two teams of reviewers independently evaluated the methodology and extracted data from each primary study. Results: Six studies were included in the meta-analysis. Risk ratios for overall mortality for adjunctive corticosteroids were 0.54 (95% confidence interval [CI], 0.38-0.79) at 1 month and 0.67 ( 95% CI, 0.49-0.93) at 3-4 months of follow-up. Numbers needed to treat, to prevent 1 death, are 9 patients in a setting without highly active antiretroviral therapy ( HAART) available and 22 patients with HAART available. Only the 3 largest trials provided data on the need for mechanical ventilation with a risk ratio of 0.37 ( 95% CI, 0.20-0.70) in favour of adjunctive corticosteroids. Conclusion: The number and size of trials investigating adjunctive corticosteroids for HIV-infected patients with PCP is small, but our results suggest a beneficial effect for patients with substantial hypoxemia.